A new study has shown that a uterine bacterium is one cause of endometriosis and that preventing the infection could prevent development of the pathology, in which tissue similar to the lining of the uterus grows in the abdominal cavity. Read More

The degradation pathways of cellular components can be shared by different molecules or selectively replace different substances and organelles. In the brain, synaptic transmission involves signaling pathways for a wide range of molecules, vesicles and receptors that require constant recycling. A proteomic study from the University of Lausanne and the University of Fribourg sheds light on brain autophagy-selective routes in adolescent, adult and aged brains. Read More

It has been previously demonstrated that the Bruton tyrosine kinase (BTK) pathway plays a key role promoting cell adhesion and chemotaxis, and that increased adhesion and aberrant chemotaxis contribute to pathogenesis of myelofibrosis (MF). At the recent EHA meeting, researchers from Telios Pharma Inc. presented preclinical data for TL-895, a novel BTK inhibitor currently in clinical development for the treatment of patients with chronic lymphocytic leukemia and MF. Read More

Beyond Air Inc. has entered into an agreement with Yissum Research Development Co. of the Hebrew University of Jerusalem to license the commercial rights for multiple neuronal nitric oxide synthase (nNOS) inhibitor candidates, currently being developed for the treatment of autism spectrum disorder (ASD) and other neurological conditions. Read More

It has been previously demonstrated that in zebrafish, the activity of UXS1, a gene that encodes UDP-glucuronate decarboxylase 1, is essential for production and organization of skeletal extracellular matrix. Now, researchers from the University of Oslo and affiliated organizations have identified a novel pathogenic variant in UXS1. Read More

Acinetobacter baumannii is commonly isolated from organ fluids of infected patients. Given that A. baumannii is inherently resistant to multiple antibiotics, new categorical antibiotics are needed that target a narrow, not broad, spectrum of bacteria. Read More

Wuhan Zhongcheng Health Bio-Pharm Technology Co. Ltd. has disclosed aromatic amine compounds acting as Bcr-Abl (Bcr-Abl1) kinase inhibitors reported to be useful for the treatment of neurodegeneration, motor neuron disease, muscular dystrophy, autoimmune disease and inflammation, viral infection, prion infection and cancer. Read More

Granulosa cell tumors (GCT) are a rare subtype of ovarian cancers, characterized by a slow clinical progression and high rates of late recurrence. With limited treatment options available apart from invasive surgery, targeted therapies would be key. In previous research, scientists at Hudson Institute of Medical Research in Australia demonstrated that targeting X-linked inhibitor of apoptosis protein (XIAP) using small-molecule inhibitors (called Smac-mimetics [SM]) in combination with other compounds could work as a therapeutic approach for GCT. Read More

Confo Therapeutics NV has entered into a research collaboration with Abcellera Biologics Inc. for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets. Read More

TYK Medicines Inc. has synthesized proteolysis targeting chimera (PROTAC) compounds comprising cereblon (CRBN) binding moieties covalently linked to EGFR (HER1; erbB1) binding moieties reported to be useful for the treatment of cancer, infections, cardiovascular, immunological, inflammatory and metabolic diseases. Read More

Gastric cancer (GC) is the fourth most common cause of cancer-related deaths, causing more than 750,000 deaths in 2020. Platinum-based 5-fluorouracil (5-FU) combinations improve survival times compared to surgery alone, but emergent treatment resistance limits long-term clinical benefits. Accordingly, there is an urgent need to develop alternative approaches to overcoming chemoresistance. Read More

Verve Therapeutics Inc. has entered into an exclusive research collaboration with Eli Lilly and Co. focused on advancing Verve’s preclinical stage in vivo gene editing program targeting lipoprotein(a) (Lp[a]), a risk factor for atherosclerotic cardiovascular disease (ASCVD), ischemic stroke, thrombosis and aortic stenosis. Read More